company background image
BH3 logo

PTC Therapeutics DB:BH3 Stock Report

Last Price

€26.40

Market Cap

€2.0b

7D

0.8%

1Y

-37.1%

Updated

26 Mar, 2024

Data

Company Financials +

BH3 Stock Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.

BH3 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

PTC Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PTC Therapeutics
Historical stock prices
Current Share PriceUS$26.40
52 Week HighUS$54.50
52 Week LowUS$16.40
Beta0.66
1 Month Change11.86%
3 Month Change3.94%
1 Year Change-37.14%
3 Year Change-34.65%
5 Year Change-21.87%
Change since IPO97.41%

Recent News & Updates

Recent updates

Shareholder Returns

BH3DE BiotechsDE Market
7D0.8%2.1%1.9%
1Y-37.1%37.0%7.3%

Return vs Industry: BH3 underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: BH3 underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is BH3's price volatile compared to industry and market?
BH3 volatility
BH3 Average Weekly Movement9.9%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: BH3 has not had significant price volatility in the past 3 months.

Volatility Over Time: BH3's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
19981,022Matt Kleinhttps://www.ptcbio.com

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.

PTC Therapeutics, Inc. Fundamentals Summary

How do PTC Therapeutics's earnings and revenue compare to its market cap?
BH3 fundamental statistics
Market cap€2.04b
Earnings (TTM)-€578.54m
Revenue (TTM)€865.89m

2.3x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BH3 income statement (TTM)
RevenueUS$937.82m
Cost of RevenueUS$732.05m
Gross ProfitUS$205.77m
Other ExpensesUS$832.38m
Earnings-US$626.60m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-8.18
Gross Margin21.94%
Net Profit Margin-66.81%
Debt/Equity Ratio-256.3%

How did BH3 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.